Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | BACE1 | P56817 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | ESR1 | P03372 | 2/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6723426 | 0.85 | CYP1A2 (0.47) | SMN1; SMN2GLACYP1A2CYP2C9CYP2C19 | |
| SCHEMBL6719887 | 0.79 | CYP1A2 (0.41) | CYP1A2CYP2C9CYP2C19MAPTESR1 | |
| SCHEMBL6717312 | 0.77 | NR5A1 (0.44) | CYP1A2CYP2C9CYP2C19ALDH1A1MAPT | |
| SCHEMBL25172613 | 0.76 | GLA (0.42) | SMN1; SMN2GLACYP1A2CYP2C9CYP2C19 | |
| SCHEMBL160991 | 0.76 | SMN1; SMN2 (0.45) | SMN1; SMN2GLACYP1A2CYP2C9CYP2C19 | |
| SCHEMBL4888139 | 0.76 | SMN1; SMN2 (0.42) | SMN1; SMN2GLACYP1A2CYP2C9CYP2C19 | |
| SCHEMBL10752997 | 0.74 | SMN1; SMN2 (0.44) | SMN1; SMN2GLACYP1A2CYP2C9CYP2C19 | |
| SCHEMBL7799554 | 0.74 | SMN1; SMN2 (0.54) | SMN1; SMN2GLACYP1A2CYP2C9CYP2C19 | |
| SCHEMBL6714209 | 0.73 | MAPT (0.41) | CYP1A2CYP2C9CYP2C19ATMALDH1A1 | |
| SCHEMBL12967934 | 0.71 | GLA (0.51) | SMN1; SMN2GLACYP1A2CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040142952-A1 | Triazoloquinazoline and pyrazolotriazolopyrimidine derivatives, medicinal compositions, adenosine a3 receptor affinity agents, ocular tension lowering agents, preparations for preventing and treating glaucoma and method of lowering ocular tension | OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) | 2004-07-22 | — | — | US | disclosed |
| EP-1364953-A1 | TRIAZOLOQUINAZOLINE AND PYRAZOLOTRIAZOLOPYRIMIDINE DERIVATIVES, MEDICINAL COMPOSITIONS, ADENOSINE A3 RECEPTOR AFFINITY AGENTS, OCULAR TENSION LOWERING AGENTS, PREPARATIONS FOR PREVENTING AND TREATING GLAUCOMA AND METHOD OF LOWERING OCULAR TENSION | OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) | 2003-11-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040142952-A1 | Triazoloquinazoline and pyrazolotriazolopyrimidine derivatives, medicinal compositions, adenosine a3 receptor affinity agents, ocular tension lowering agents, preparations for preventing and treating glaucoma and method of lowering ocular tension | ADORA3, ADORA1, ADORA2A | SMN1; SMN2 4846/4885GLA 2891/4885CYP1A2 229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.